Effect of pregnancy on vasopressin-mediated responses in guinea-pig uterine arteries with intact and denuded endothelium.

A. Jovanovic,L. Grbović,S. Jovanović,I. Ẑikić

DOI: https://doi.org/10.1016/0014-2999(95)00188-Q

IF: 5.195

1995-07-04

European Journal of Pharmacology

Abstract:

What problem does this paper attempt to address?

Virulence‐Free Reconstituted Synthetic Nanopathogen Empowered by Timely‐Activating TLR Agonist Promotes Heterologous Cancer Immunotherapy with Depletion of Tumor‐Specific Treg Cells

Sang Nam Lee,Sei Hyun Park,Jin‐Ho Choi,Jang Hun Heo,Min‐Ho Lee,Sang‐Seok Oh,Young‐Woock Noh,Yong Taik Lim

DOI: https://doi.org/10.1002/adfm.202411747

IF: 19

2024-11-05

Advanced Functional Materials

Abstract:As an immunotherapeutic nanomedicine platform exploiting the heterologous immunity of live pathogens, the authors develop a virulence‐free reconstituted synthetic nanopathogen by the reconstitution of the cell wall skeleton of disrupted Mycobacterium bovis and the incorporation of timely‐activating Toll‐like receptor 7/8 agonists of which multifaceted activities can be switchable by endolysosomal GILT enzymes. The heterologous immunity of live pathogens leads to the emergence of this approach as a pivotal component in cancer immunotherapy. However, virulence, inflammatory‐related toxicity, and the induction of Treg cells after treatment hinder their clinical translation. Here, to exploit the heterologous immunity of live pathogens without risks, a virulence‐free reconstituted synthetic nanopathogen (RSnP) is developed by the cell wall skeleton of disrupted Mycobacterium bovis and the incorporation of timely‐activating Toll‐like receptor 7/8 agonists of which multifaceted activities can be promoted by endolysosomal enzymes. Immunization with RSnP, even without tumor‐specific antigens, exhibits potent antitumor efficacy against melanoma, breast cancer, and bladder cancer by promoting antitumor effector cells (CD8+ T cells, NK cells, M1 macrophages, and Th17 cells) and proinflammatory cytokines (IL‐12p70, TNF‐α, and IL‐6) while simultaneously mitigating immunosuppressive myeloid cells (MDSCs and M2 macrophages) in the tumor microenvironment, surpassing the therapeutic efficacies of approved live‐BCG drug and mRNA vaccine. The increase in CCR8+Foxp3+ Treg cells induced to counteract RSnP treatment can be attenuated by anti‐CCR8 antibody, a depletion antibody for tumor‐specific Treg cells, to synergize therapeutic efficacy with relieved autoimmunity. RSnP can be a therapeutic nanomedicine platform across heterologous cancers and emerging infectious virus variants with minimized toxicity.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Abstract 6743: Identifying new cellular adjuvants for cancer vaccines and immunotherapies

Joseph Rucker,Nnenna Nwogu,Nicholas M. Molino,Ami Snyder,Jonathan T. Sullivan,Benjamin J. Doranz

DOI: https://doi.org/10.1158/1538-7445.am2024-6743

IF: 11.2

2024-04-04

Cancer Research

Abstract:Background: Cancer vaccines represent a promising strategy for antitumor immunotherapy. Despite considerable research efforts and progress, the effectiveness of cancer vaccines remains a challenge. This is primarily due to relatively low immune responses against tumors, stemming from issues of poor immunogenicity and the immunosuppressive microenvironment commonly found in many solid tumors. Use of an optimal adjuvant can augment immune responses against tumor antigens and guide them towards a specific adaptive immune enhancement. Dendritic cells (DCs) play a primary role in initiating immunes response to vaccines, often through activation of toll-like receptors (TLRs). Identifying novel immunomodulatory proteins that regulate DCs or TLR activation can identify novel adjuvant candidates with applications for cancer immunotherapy. Methods: We constructed a Membrane Proteome Array (MPA) encompassing ~6,000 structurally intact human membrane proteins in their native conformation (94% of the entire membrane proteome) and used it to screen for cellular proteins that can modulate response to vaccination through DCs and TLRs. To identify proteins that interact with TLRs, the library was expressed in live TLR reporter cells, and these cells were tested for response to known activators. In addition, cells expressing the MPA were presented to DCs to identify membrane proteins that modulate DC activity. TLR-expressing cell activation was measuring using an NF-kB-activated luciferase reporter, while DC assays used upregulation of cell surface markers (CD80, CD83, and MHCII) to measure the activation of immature monocyte-derived dendritic cells. Results: Screening of TLR2, TLR3, and TLR5 reporter cell lines identified both known and novel regulators of TLR activation. Activators common to several TLRs were identified as well as activators unique to individual TLRs. Screening of primary human DCs likewise identified known regulators of activation (for example CD40L) and several novel targets. Putative novel regulators of DC activation are being further investigated to determine their biological significance. Conclusion: Discovering novel immunomodulatory targets and proteins that regulate DCs and TLR activation can identify novel adjuvant candidates with targeted immune outcomes, such as immune stimulating and anti-cancer responses. This study identified novel regulators of immune activation which are being further investigated as adjuvant candidates for cancer vaccines. Citation Format: Joseph Rucker, Nnenna Nwogu, Nicholas M. Molino, Ami Snyder, Jonathan T. Sullivan, Benjamin J. Doranz. Identifying new cellular adjuvants for cancer vaccines and immunotherapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6743.

oncology
Enhanced Vaccine Immunogenicity Enabled by Targeted Cytosolic Delivery of Tumor Antigens into Dendritic Cells

Nicholas L. Truex,Aurélie Rondon,Simon L. Rössler,Cameron C. Hanna,Yehlin Cho,Bin-You Wang,Coralie M. Backlund,Emi A. Lutz,Darrell J. Irvine,Bradley L. Pentelute,Aurélie Rondon,Simon L. Rössler

DOI: https://doi.org/10.1021/acscentsci.3c00625

IF: 18.2

2023-09-14

ACS Central Science

Abstract:Molecular vaccines comprising antigen peptides and inflammatory cues make up a class of therapeutics that promote immunity against cancer and pathogenic diseases but often exhibit limited efficacy. Here, we engineered an antigen peptide delivery system to enhance vaccine efficacy by targeting dendritic cells and mediating cytosolic delivery. The delivery system consists of the nontoxic anthrax protein, protective antigen (PA), and a single-chain variable fragment (scFv) that recognizes the XCR1 receptor on dendritic cells (DCs). Combining these proteins enabled selective delivery of the N-terminus of lethal factor (LFN) into XCR1-positive cross-presenting DCs. Incorporating immunogenic epitope sequences into LFN showed selective protein translocation in vitro and enhanced the priming of antigen-specific T cells in vivo. Administering DC-targeted constructs with tumor antigens (Trp1/gp100) into mice bearing aggressive B16-F10 melanomas improved mouse outcomes when compared to free antigen, including suppressed tumor growth up to 58% at 16 days post tumor induction (P < 0.0001) and increased survival (P = 0.03). These studies demonstrate that harnessing DC-targeting anthrax proteins for cytosolic antigen delivery significantly enhances the immunogenicity and antitumor efficacy of cancer vaccines.

chemistry, multidisciplinary
Abstract 5747: A novel combination therapy of arenavirus vectors and PD1-IL2v strongly potentiates tumor specific T cell responses resulting in synergistic anti-tumor efficacy

Judith Strauss,Diana Reckendorfer,Kimberly Pojar,Laura Codarri Deak,Valeria Nicolini,Roger Sutmuller,Christian Klein,Pablo Umaña,Klaus K. Orlinger,Henning Lauterbach

DOI: https://doi.org/10.1158/1538-7445.am2023-5747

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract It is undisputed that CD8 T cells play a critical role in controlling tumor growth and killing tumor cells, and that tumor specific T cells are essential for clinical responses to immune checkpoint inhibitors. Yet, the induction and maintenance of functional tumor antigen specific T cell responses represent still one of the greatest challenges in cancer immunotherapy. Therapeutic cancer vaccines based on engineered arenavirus vectors have been shown preclinically to overcome self-tolerance to tumor associated antigens (TAA) and mount unprecedented T cell responses, both, in preclinical tumor models as well as HPV16+ cancer patients in an ongoing Phase 1/2 trial. The novel PD-1 targeted IL-2 variant (PD1-IL2v) was created to maximize the potency of IL-2R activation of effector T cells while overcoming the toxicities of wildtype IL-2. Cis binding of PD1-IL2v to PD-1 and IL-2Rβγ on the same cell was recently shown to promote differentiation of stem-like CD8 T cells into better effectors and was therefore identified as an ideal compound for combination therapies with arenavirus vectors. Combination of vectors encoding tumor associated foreign or self-antigens with PD1-IL2v lead to a massive, up to 60-fold, increase of peripheral tumor specific CD8 T cell numbers compared to vector treatment alone. Notably, frequency of peripheral regulatory T cells was not enhanced by this combination. The massive increase of TAA specific CD8 T cells was associated with synergistic anti-tumor efficacy in two independent tumor models, resulting in longer survival times and up to 60% complete responders. Complete tumor clearance resulted in a stable memory T cell population and protection against tumor re-challenge. Ongoing studies will address modifications of the tumor microenvironment and further characterization of tumor infiltrating T cells upon combination therapy. These preclinical data establish the combination of arenavirus vectors and PD1-IL2v as a promising next generation cancer immunotherapy. Citation Format: Judith Strauss, Diana Reckendorfer, Kimberly Pojar, Laura Codarri Deak, Valeria Nicolini, Roger Sutmuller, Christian Klein, Pablo Umaña, Klaus K. Orlinger, Henning Lauterbach. A novel combination therapy of arenavirus vectors and PD1-IL2v strongly potentiates tumor specific T cell responses resulting in synergistic anti-tumor efficacy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5747.

oncology
Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity

Xiaofei Yu,Wenjie Liu,Shixian Chen,Xueqian Cheng,Patrick A Paez,Tuanwei Sun,Fang Yuan,Chunyan Wei,Joseph W Landry,Andrew S Poklepovic,Harry D Bear,John R Subjeck,Elizabeth Repasky,Chunqing Guo,Xiang-Yang Wang

DOI: https://doi.org/10.1136/jitc-2020-001595

IF: 12.469

2021-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Background The efficacy of cancer immunotherapy can be limited by the poor immunogenicity of cancer and the immunosuppressive tumor microenvironment (TME). Immunologically programming the TME and creating an immune-inflamed tumor phenotype is critical for improving the immune-responsiveness of cancers. Here, we interrogate the immune modulator Flagrp170, engineered via incorporation of a pathogen-associated molecular pattern (ie, flagellin) into an immunostimulatory chaperone molecule, in transforming poorly immunogenic tumors and establishing a highly immunostimulatory milieu for immune augmentation. Methods Multiple murine cancer models were used to evaluate the immunostimulatory activity, antitumor potency, and potential side effects of Flagrp170 on administration into the tumors using a replication impaired adenovirus. Antibody neutralization and mice deficient in pattern recognition receptors, that is, toll-like receptor 5 (TLR5) and NOD like receptor (NLR) family caspase activation and recruitment domain (CARD) domain-containing protein 4 (NLRC4), both of which can recognize flagellin, were employed to understand the immunological mechanism of action of the Flagrp170. Results Intratumoral delivery of mouse or human version of Flagrp170 resulted in robust inhibition of multiple malignancies including head and neck squamous cell carcinoma and breast cancer, without tissue toxicities. This in situ Flagrp170 treatment induced a set of cytokines in the TME known to support Th1/Tc1-dominant antitumor immunity. Additionally, granulocyte macrophage colony-stimulating factor derived from mobilized CD8 + T cells was involved in the therapeutic activity of Flagrp170. We also made a striking finding that NLRC4, not TLR5, is required for Flagrp170-mediated antitumor immune responses. Conclusion Our results elucidate a novel immune-potentiating activity of Flagrp170 via engaging the innate pattern recognition receptor NLRC4, and support its potential clinical use to reshape cancer immune phenotype for overcoming therapeutic resistance.

oncology,immunology
Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy

C Tosch,M Geist,C Ledoux,C Ziller-Remi,S Paul,P Erbs,N Corvaia,P Von Hoegen,J-M Balloul,H Haegel

DOI: https://doi.org/10.1038/cgt.2008.85

Abstract:The delivery of stimulatory signals to dendritic cells (DCs) in the tumor microenvironment could be an effective means to break tumor-induced tolerance. The work presented here evaluates the immunostimulatory properties of pathogen-associated molecular patterns (PAMPs), microbial molecules which bind Toll-like receptors and deliver activating signals to immune cells, when expressed in tumor cells using adenoviral (Ad) vectors. In vitro, transduction of A549 tumor cells with Ad vectors expressing either flagellin from Listeria monocytogenes or P40 protein from Klebsiella pneumoniae induced the maturation of human monocyte-derived DCs in co-cultures. In mixed lymphocyte reactions (MLRs), Ad-flagellin and Ad-P40 transduction of tumor cells stimulated lymphocyte proliferation and the secretion of IFN-gamma. In vivo, these vectors were used either as stand-alone immunoadjuvants injected intratumorally or as vaccine adjuvants combined with a tumor antigen-expressing vector. When Ad-PAMPs were administered intratumorally to mice bearing subcutaneous syngeneic B16F0-CAR (cocksackie-adenovirus receptor) melanomas, tumor progression was transiently inhibited by Ad-P40. In a therapeutic vaccine setting, the combination of Ad-MUC1 and Ad-PAMP vectors injected subcutaneously delayed the growth of implanted RenCa-MUC1 tumors and improved tumor rejection when compared with vaccination with Ad-MUC1 alone. These results suggest that Ad-PAMPs could be effective immunoadjuvants for cancer immunotherapy.
Exploiting bacterial-origin immunostimulants for improved vaccination and immunotherapy: current insights and future directions

Guangyu Wang,Yongkang Wang,Fang Ma

DOI: https://doi.org/10.1186/s13578-024-01207-7

2024-02-18

Cell & Bioscience

Abstract:Vaccination is a valid strategy to prevent and control newly emerging and reemerging infectious diseases in humans and animals. However, synthetic and recombinant antigens are poor immunogenic to stimulate efficient and protective host immune response. Immunostimulants are indispensable factors of vaccines, which can promote to trigger fast, robust, and long-lasting immune responses. Importantly, immunotherapy with immunostimulants is increasing proved to be an effective and promising treatment of cancer, which could enhance the function of the immune system against tumor cells. Pattern recognition receptors (PRRs) play vital roles in inflammation and are central to innate and adaptive immune responses. Toll-like receptors (TLRs)-targeting immunostimulants have become one of the hotspots in adjuvant research and cancer therapy. Bacterial-origin immunoreactive molecules are usually the ligands of PRRs, which could be fast recognized by PRRs and activate immune response to eliminate pathogens. Varieties of bacterial immunoreactive molecules and bacterial component-mimicking molecules have been successfully used in vaccines and clinical therapy so far. This work provides a comprehensive review of the development, current state, mechanisms, and applications of bacterial-origin immunostimulants. The exploration of bacterial immunoreactive molecules, along with their corresponding mechanisms, holds immense significance in deepening our understanding of bacterial pathogenicity and in the development of promising immunostimulants.

biochemistry & molecular biology
Abstract 481: Proteomimetic polymers limit tumor growth in multiple models via potent antigen-specific T cell activation

Max Wang,Miran Choi,Bin Zhang,Nathan Gianneschi

DOI: https://doi.org/10.1158/1538-7445.am2024-481

IF: 11.2

2024-03-31

Cancer Research

Abstract:Background: Patient-specific cancer vaccines derived from tumor antigen have been explored as a promising therapeutic strategy, however, challenges delivering vaccine components in a coordinated fashion to elicit antitumor responses remain. To overcome these, we utilize a novel nanoplatform called the Protein-Like Polymer (PLP), which allows for sustained and targeted delivery of tumor antigens in conjunction with adjuvants. Methods: PLPs containing peptide antigens were synthesized via ring-opening metathesis polymerization (ROMP) and characterized. A library of compounds with different sidechain linkage chemistries, degrees of polymerization (DP), and inclusion/exclusion of Oligo-ethylene glycol (OEG) were made to determine design rules for immune activation. Cell uptake and functional assays using payload-specific T Cells were conducted. Immunization in three independent tumor models was done to show generalizability. Ability of PLPs to co-deliver adjuvants was tested by electrostatically coupling small molecule STING agonist, 2'3' cGAMP. Results: Conjugating peptide antigens to the polymer via a cleavable disulfide linkage, which reduces intracellularly in APCs, resulted in increased endosomal localization, higher levels of induced T cell proliferation, cytokine production, and expression of activation markers in CTLs and APCs. Incorporating a diluent amount of OEG side chains reduced enzymatic degradation while increasing immunogenicity and uptake. Additionally, increasing the DP, and therefore the density of antigen side chains, further improved vaccine efficacy and resistance to proteolysis. Antigen-PLP conjugates enhanced dendritic cell activation and T-cell response only when paired with cells from their cognate system, with no activity in immune cells not expressing receptors for the payload demonstrating antigen-specificity. Mice bearing established B16F10, MC38, or TC-1 tumors treated with PLPs containing gp100, adpgk, or E7 respectively all showed increased survival times, reduced tumor burden with corresponding changes in immune cell profiles, and immunological memory upon rechallenge. Impressively, mice treated with STING-PLP complexes had significantly smaller tumors vs control at day 14 (0.038g vs 0.76g; p <0.0001) and allowed for subcutaneous administration of 2'3' cGAMP, which traditionally requires intratumoral injection. Studies on the effects of vaccinating with pools of neoantigens multiplexed onto one PLP are ongoing. Conclusion: This work validates the ability of PLPs to overcome major limitations in cancer vaccine development. The modularity of the platform allows for complex nano-architectures including systems capable of delivering challenging compounds, ie small molecule STING agonists, subcutaneously through electrostatic coupling, highlighting its potential to revolutionize cancer vaccinology. Citation Format: Max Wang, Miran Choi, Bin Zhang, Nathan Gianneschi. Proteomimetic polymers limit tumor growth in multiple models via potent antigen-specific T cell activation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 481.

oncology
Pattern recognition receptors and their nano-adjuvants for cancer immunotherapy

Zhen Li,Isra Rana,Gyungdeuk Park,Jinwoo Lee,Chae Eun Park,Jutaek Nam

DOI: https://doi.org/10.1007/s40005-023-00633-y

2023-09-22

Journal of Pharmaceutical Investigation

Abstract:Pattern recognition receptors (PRRs) are crucial immune modulators that orchestrate innate and adaptive immune systems for the regulation of inflammatory responses. Several PRR families and their ligands associated with immune modulation have been identified, which promoted the development of natural and synthetic PRR agonistic ligands as adjuvants in immunotherapy applications. However, conventional adjuvants are mainly based on small molecules, peptides, lipids, and oligonucleotides, which suffer from unfavorable drug-like properties for in vivo applications, including vulnerability to biodegradation, undesirable pharmacokinetic profiles, and poor cellular uptake. Nanoparticle formulation is a promising approach for addressing the issues with conventional adjuvants.

English Else
Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

Huan Yan,Guibin Lin,Zhanyan Liu,Fei Gu,Yuan Zhang

DOI: https://doi.org/10.1016/j.actbio.2023.02.034

IF: 10.633

2023-03-16

Acta Biomaterialia

Abstract:Immunostimulatory cues play an important role in priming antitumor immunity and promoting the efficacy of subunit cancer vaccines. However, the clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote vaccine efficacy, we develop vaccine formulations which integrate three key elements: (1) a nano-adjuvant formulated by conjugating an agonistic anti-CD40 monoclonal antibody (αCD40) to the surface of a polyIC-loaded lipid nanoparticle, (2) a peptide amphiphile containing an optimized CD8 + T-cell epitope that derived from a melanoma antigen gp100, (3) an agonistic anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In a syngeneic mouse model of melanoma, the vaccine formulations enhanced innate immunity and activated multiple innate immune signaling pathways within draining lymph nodes, as well as promoted antigen-specific immune responses and reduced immunosuppression in the tumor microenvironment, leading to profound tumor growth inhibition and prolonged survival. Thus, our vaccine formulations represent an attractive strategy to stimulate antitumor immunity and control tumor progression. Statement of significance The clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote the antitumor immunity of subunit vaccines, we develop novel vaccine formulations that integrate multifunctional modalities including (1) a nano-adjuvant containing anti-CD40 monoclonal antibody (αCD40) and TLR3 agonist which activate innate immunity through diverse signaling pathways, (2) a peptide amphiphile containing an optimized CD8 + T-cell epitope from tumor antigen, (3) an anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In this study, our vaccine formulations stimulate superior antitumor immunity and control tumor progression. The above nano-engineered platform and immunogenic biomacromolecules can be further applied to other T-cell-inducing vaccines.

engineering, biomedical,materials science, biomaterials
Which postsynaptic action of dopamine is mediated by cycle AMP?

B. Libet

DOI: https://doi.org/10.1016/0024-3205(79)90037-7

1979-03-19

Life Science

Abstract:
Abstract A021: A cancer immunotherapy modality based on dendritic cell reprogramming in vivo

Ervin Ascic,Fritiof Åkerström,Malavika Sreekumar Nair,André Rosa,Ilia Kurochkin,Olga Zimmermannova,Xavier Catena,Nadezhda Rotankova,Charlotte Veser,Michal Rudnik,Tommaso Ballocci,Tiffany Schärer,Xiaoli Huang,Maria de Rosa Torres,Emilie Renaud,Marta Velasco Santiago,Özcan Met,David Askmyr,Malin Lindstedt,Lennart Greiff,Laure-Anne Ligeon,Irina Agarkova,Inge Marie Svane,Cristiana Pires,Fábio Fiúza Rosa,Carlos-Filipe Pereira

DOI: https://doi.org/10.1158/2326-6074.tumimm24-a021

IF: 10.1

2024-10-19

Cancer Immunology Research

Abstract:Cancer immunotherapy leads to long-term survival, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment (TME). A growing body of evidence indicates that intratumoral conventional type 1 dendritic cells (cDC1) are required to mount effective Tcell-mediated antitumor immunity and associate with better response to immune checkpoint blockade (ICB) therapy. However, approaches to generate cDC1s at clinical scale for immunotherapy have met limited success. We have previously demonstrated that overexpression of the transcription factors PU.1, IRF8 and BATF3 (PIB) drives cell fate reprogramming of cancer cells into functional antigen-presenting cDC1-like cells. Here, we investigated whether in vivo reprogramming of cancer cells into immunogenic antigen-presenting cDC1s can elicit systemic and durable antitumor immunity and explored the potential of in vivo delivery of PIB as a novel cancer immunotherapy modality. In vivo cDC1 reprogramming and antitumor efficacy were assessed upon subcutaneous implantation of in vitro transduced cancer cells in xenografts and ICB-resistant cDC1-dependent mouse syngeneic models. The impact of in vivo reprogramming in the TME was assessed using flow cytometry, single-cell transcriptomics, immunohistochemistry and microscopy. Tumor spheroids generated with human cancer cells in combination with cancer-associated fibroblasts or anti-inflammatory cytokines were used to investigate the impact of immunosuppressive microenvironment in cDC1 reprogramming. To select the optimal platform for in vivo delivery of PIB, we benchmarked PIB-encoding replication-deficient adenoviral (AdV), adeno-associated viral (AAV) and lentiviral (LV) vectors using mouse and human cancer cell lines and patient-derived cancer spheroids. Intratumoral delivery of PIB was performed in B16 syngeneic model to confirm in vivo efficacy induced by the gene therapy product.In vivo reprogramming to cDC1s drove complete responses (CR) in YUMM1.7 (100% CR), BRAFV600ECOX2KO (50% CR) and B2905 (80% CR) models and synergized with ICBs leading to 40% CR in B16 model, expansion of tumor-reactive T-cells and abscopal effect. Reprogrammed cancer cells recruited lymphocytes, promoted formation of tertiary lymphoid-like structures and expansion of polyclonal cytotoxic T cells. PIB-transduced human cancer cells acquired cDC1 and antigen-presentation markers in vivo with similar efficiency and kinetics as in vitro independently of immunosuppressive cells and cytokines. AdV was selected as the most efficient vector for in vivo delivery of PIB. Intra-tumoral injection of PIB-encoding AdV allowed in situ phenotypic reprogramming, enhanced infiltration of cytotoxic T cells and drove 50% CR, abscopal effect, long-term immune memory and protection against local and metastatic re-challenge. These findings provide preclinical proof-of-concept for an off-the-shelf, personalized cancer immunotherapy based on in situ cDC1 reprogramming, paving the way for first-in-human trials. Citation Format: Ervin Ascic, Fritiof Åkerström, Malavika Sreekumar Nair, André Rosa, Ilia Kurochkin, Olga Zimmermannova, Xavier Catena, Nadezhda Rotankova, Charlotte Veser, Michal Rudnik, Tommaso Ballocci, Tiffany Schärer, Xiaoli Huang, Maria de Rosa Torres, Emilie Renaud, Marta Velasco Santiago, Özcan Met, David Askmyr, Malin Lindstedt, Lennart Greiff, Laure-Anne Ligeon, Irina Agarkova, Inge Marie Svane, Cristiana Pires, Fábio Fiúza Rosa, Carlos-Filipe Pereira. A cancer immunotherapy modality based on dendritic cell reprogramming in vivo [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A021.

oncology,immunology
STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation

Bo-Dou Zhang,Jun-Jun Wu,Wen-Hao Li,Hong-Guo Hu,Lang Zhao,Pei-Yang He,Yu-Fen Zhao,Yan-Mei Li

DOI: https://doi.org/10.1007/s12274-022-4282-x

IF: 9.9

2022-04-18

Nano Research

Abstract:Immunostimulatory therapies based on pattern recognition receptors (PRRs) have emerged as an effective approach in the fight against cancer, with the ability to recruit tumor-specific lymphocytes in a low-immunogenicity tumor environment. The agonist cyclic dinucleotides (CDNs) of the stimulator of interferon gene (STING) are a group of very promising anticancer molecules that increase tumor immunogenicity by activating innate immunity. However, the tumor immune efficacy of CDNs is limited by several factors, including relatively narrow cytokine production, inefficient delivery to STING, and rapid clearance. In addition, a single adjuvant molecule is unable to elicit a broad cytokine response and thus cannot further amplify the anticancer effect. To address this problem, two or more agonist molecules are often used together to synergistically enhance immune efficacy. In this work, we found that a combination of the STING agonist CDGSF and the Toll-like receptor 7/8 (TLR7/8) agonist 522 produced a broader cytokine response. Subsequently, we developed multicomponent nanovaccines (MCNVs) consisting of a PC7A polymer as a nanocarrier encapsulating the antigen OVA and adjuvant molecules. These MCNVs activate bone marrow-derived dendritic cells (BMDCs) to produce multiple proinflammatory factors that promote antigen cross-presentation to stimulate specific antitumor T-cell responses. In in vivo experiments, we observed that MCNVs triggered a strong T-cell response in tumor-infiltrating lymphocytes, resulting in significant tumor regression and, notably, a 100% survival rate in mice through 25 days without other partnering therapies. These data suggest that our nanovaccines have great potential to advance cancer immunotherapy with increased durability and potency.

materials science, multidisciplinary,chemistry, physical,physics, applied,nanoscience & nanotechnology
Outer Membrane Vesicle‐Based Nanohybrids Target Tumor‐Associated Macrophages to Enhance Trained Immunity‐Related Vaccine‐Generated Antitumor Activity

Jie Liang,Fei Zhu,Keman Cheng,Nana Ma,Xiaotu Ma,Qingqing Feng,Chen Xu,Xiaoyu Gao,Xinwei Wang,Jian Shi,Xiao Zhao,Guangjun Nie

DOI: https://doi.org/10.1002/adma.202306158

IF: 29.4

2023-08-31

Advanced Materials

Abstract:Trained immunity refers to the innate immune system building memory‐like features in response to subsequent infections and vaccinations. Compared with classical tumor vaccines, trained immunity‐related vaccines (TIrV) are independent of tumor‐specific antigens. Bacterial outer membrane vesicles (OMVs) contain an abundance of PAMPs and have the potential to act as TIrV‐inducer, but face challenges in endotoxin tolerance, systemic delivery, long‐term training, and trained tumor‐associated macrophage (TAM)‐mediated antitumor phagocytosis. Here, we developed an OMV‐based TIrV, OMV nanohybrids (OMV‐SIRPα@CaP/GM‐CSF) for exerting vaccine‐enhanced antitumor activity. In the bone marrow, GM‐CSF‐assisted OMVs trained bone marrow progenitor cells and monocytes, which were inherited by TAMs. In tumor tissues, SIRPα‐Fc‐assisted OMVs triggered TAM‐mediated phagocytosis. This TIrV can be identified by metabolic and epigenetic rewiring using transposase‐accessible chromatin (ATAC) and transcriptome sequencing. Furthermore, we found that the TIrV‐mediated antitumor mechanism in MC38 tumor model (TAM‐hot & T cell‐cold) is trained immunity and activated T cell response, whereas in B16‐F10 tumor model (T cell‐hot & TAM‐cold) is primarily mediated by trained immunity. Our study not only developed and identified OMV‐based TIrV, but also investigated the trained immunity signatures and therapeutic mechanisms, providing a basis for further vaccination strategies. This article is protected by copyright. All rights reserved

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization

Justin C Jagodinsky,Amber M Bates,Paul A Clark,Raghava N Sriramaneni,Thomas C Havighurst,Ishan Chakravarty,Erin J Nystuen,KyungMann Kim,Paul M Sondel,Won Jong Jin,Zachary S Morris

DOI: https://doi.org/10.1136/jitc-2022-005103

IF: 12.469

2022-10-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Radiation therapy (RT) has been demonstrated to generate an in situ vaccination (ISV) effect in murine models and in patients with cancer; however, this has not routinely translated into enhanced clinical response to immune checkpoint inhibition (ICI). We investigated whether the commonly used vaccine adjuvant, monophosphoryl lipid A (MPL) could augment the ISV regimen consisting of combination RT and ICI. Materials/methods We used syngeneic murine models of melanoma (B78) and prostate cancer (Myc-CaP). Tumor-bearing mice received either RT (12 Gy, day 1), RT+anti-CTLA-4 (C4, day 3, 6, 9), MPL (20 μg IT injection days 5, 7, 9), RT+C4+MPL, or PBS control. To evaluate the effect of MPL on the irradiated tumor microenvironment, primary tumor with tumor draining lymph nodes were harvested for immune cell infiltration analysis and cytokine profiling, and serum was collected for analysis of antitumor antibody populations. Results Combination RT+C4+MPL significantly reduced tumor growth, increased survival and complete response rate compared with RT+C4 in both B78 and Myc-CaP models. MPL favorably reprogrammed the irradiated tumor-immune microenvironment toward M1 macrophage and Th1 TBET + CD4 + T cell polarization. Furthermore, MPL significantly increased intratumoral expression of several Th1-associated and M1-associated proinflammatory cytokines. In co-culture models, MPL-stimulated macrophages directly activated CD8 T cells and polarized CD4 cells toward Th1 phenotype. MPL treatment significantly increased production of Th1-associated, IgG2c antitumor antibodies, which were required for and predictive of antitumor response to RT+C4+MPL, and enabled macrophage-mediated antibody-dependent direct tumor cell killing by MPL-stimulated macrophages. Macrophage-mediated tumor cell killing was dependent on FcγR expression. In metastatic models, RT and MPL generated a systemic antitumor immune response that augmented response to ICIs. This was dependent on macrophages and CD4 + but not CD8+T cells. Conclusions We report the potential for MPL to augment the ISV effect of combination RT+C4 through FcγR, macrophage, and TBET + CD4 + Th1 cell dependent mechanisms. To our knowledge, this is the first report describing generation of a CD8 + T cell-independent, Th1 polarized, systemic antitumor immune response with subsequent generation of immunologic memory. These findings support the potential for vaccine adjuvants to enhance the efficacy of in situ tumor vaccine approaches.

oncology,immunology
Vaccination against neoantigens induced in cross-priming cDC1 in vivo

Emily S. Clark,Ana Paula Benaduce,Wasif N. Khan,Olivier Martinez,Eli Gilboa

DOI: https://doi.org/10.1007/s00262-023-03597-y

IF: 6.63

2024-01-18

Cancer Immunology Immunotherapy

Abstract:The conventional type 1 dendritic cells (cDC1) play a pivotal role in protective immunity against pathogens and cancer. However, their low frequency in the blood and tissues limits their use in immune therapy. We have recently described a method to vaccinate against neoantigens that are induced in tumor cells by targeted delivery of a TAP siRNA to dendritic cells using a TLR9 binding CpG oligonucleotide. Since TLR9 is also expressed in immune suppressive myeloid populations TLR9 targeting could reduce the effectiveness of this approach. Here, we describe a modular multivalent antibody platform to target the TAP siRNA to resident Clec9a expressing cDC1 and show that it leads to selective and sustained TAP downregulation in cDC1 and inhibits tumor growth in mice more effectively than CpG targeted siRNA. To induce DC maturation an agonistic CD40 antibody was administered to the siRNA treated mice. To obviate the need for a second drug formulation and reduce the risk of toxicity, we exploited the multivalent nature of this targeting platform to co-deliver the TAP siRNA and a DC maturation agent, a CpG containing oligonucleotide, to cDC1 in vivo and show that it was more effective than Clec9a targeting of TAP siRNA in combination with CD40 antibody. This study describes a way to manipulate the function of cDC1 cells in vivo using a broadly applicable antibody-based targeting platform to deliver multiple biological agents to specific cells in vivo to potentiate (immune) therapy and to probe the biology of specific cell types in their natural settings.

oncology,immunology
Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity

Tsukasa Seya,Hiroaki Shime,Yohei Takeda,Megumi Tatematsu,Ken Takashima,Misako Matsumoto

DOI: https://doi.org/10.1111/cas.12824

IF: 5.7

2015-11-18

Cancer Science

Abstract:Immune-enhancing adjuvants usually targets antigen (Ag)-presenting cells to tune up cellular and humoral immunity. CD141(+) dendritic cells (DC) represent the professional Ag-presenting cells in humans. In response to microbial pattern molecules, these DCs upgrade the maturation stage sufficient to improve cross-presentation of exogenous Ag, and upregulation of MHC and costimulators, allowing CD4/CD8 T cells to proliferate and liberating cytokines/chemokines that support lymphocyte attraction and survival. These DCs also facilitate natural killer-mediated cell damage. Toll-like receptors (TLRs) and their signaling pathways in DCs play a pivotal role in DC maturation. Therefore, providing adjuvants in addition to Ag is indispensable for successful vaccine immunotherapy for cancer, which has been approved in comparison with antimicrobial vaccines. Mouse CD8α(+) DCs express TLR7 and TLR9 in addition to the TLR2 family (TLR1, 2, and 6) and TLR3, whereas human CD141(+) DCs exclusively express the TLR2 family and TLR3. Although human and mouse plasmacytoid DCs commonly express TLR7/9 to respond to their agonists, the results on mouse adjuvant studies using TLR7/9 agonists cannot be simply extrapolated to human adjuvant immunotherapy. In contrast, TLR2 and TLR3 are similarly expressed in both human and mouse Ag-presenting DCs. Bacillus Calmette-Guerin peptidoglycan and polyinosinic-polycytidylic acid are representative agonists for TLR2 and TLR3, respectively, although they additionally stimulate cytoplasmic sensors: their functional specificities may not be limited to the relevant TLRs. These adjuvants have been posted up to a certain achievement in immunotherapy in some cancers. We herein summarize the history and perspectives of TLR2 and TLR3 agonists in vaccine-adjuvant immunotherapy for cancer.

oncology
Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity

Judit Svensson-Arvelund,Sara Cuadrado-Castano,Gvantsa Pantsulaia,Kristy Kim,Mark Aleynick,Linda Hammerich,Ranjan Upadhyay,Michael Yellin,Henry Marsh,Daniel Oreper,Suchit Jhunjhunwala,Christine Moussion,Miriam Merad,Brian D. Brown,Adolfo García-Sastre,Joshua D. Brody

DOI: https://doi.org/10.1038/s41467-022-34791-8

IF: 16.6

2022-11-22

Nature Communications

Abstract:Abstract Immunotherapies directly enhancing anti-tumor CD8 + T cell responses have yielded measurable but limited success, highlighting the need for alternatives. Anti-tumor T cell responses critically depend on antigen presenting dendritic cells (DC), and enhancing mobilization, antigen loading and activation of these cells represent an attractive possibility to potentiate T cell based therapies. Here we show that expansion of DCs by Flt3L administration impacts in situ vaccination with oncolytic Newcastle Disease Virus (NDV). Mechanistically, NDV activates DCs and sensitizes them to dying tumor cells through upregulation of dead-cell receptors and synergizes with Flt3L to promote anti-tumor CD8 + T cell cross-priming. In vivo, Flt3L-NDV in situ vaccination induces parallel amplification of virus- and tumor-specific T cells, including CD8 + T cells reactive to newly-described neoepitopes, promoting long-term tumor control. Cross-presenting conventional Type 1 DCs are indispensable for the anti-tumor, but not anti-viral, T cell response, and type I IFN-dependent CD4 + Th1 effector cells contribute to optimal anti-tumor immunity. These data demonstrate that mobilizing DCs to increase tumor antigen cross-presentation improves oncolytic virotherapy and that neoepitope-specific T cells can be induced without individualized, ex vivo manufactured vaccines.

multidisciplinary sciences
Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells

Faezzah Baharom,Ramiro A. Ramirez-Valdez,Kennedy K. S. Tobin,Hidehiro Yamane,Charles-Antoine Dutertre,Ahad Khalilnezhad,Glennys V. Reynoso,Vincent L. Coble,Geoffrey M. Lynn,Matthew P. Mulè,Andrew J. Martins,John P. Finnigan,Xiao Meng Zhang,Jessica A. Hamerman,Nina Bhardwaj,John S. Tsang,Heather D. Hickman,Florent Ginhoux,Andrew S. Ishizuka,Robert A. Seder

DOI: https://doi.org/10.1038/s41590-020-00810-3

IF: 30.5

2020-11-02

Nature Immunology

Abstract:Personalized cancer vaccines are a promising approach for inducing T cell immunity to tumor neoantigens. Using a self-assembling nanoparticle vaccine that links neoantigen peptides to a Toll-like receptor 7/8 agonist (SNP-7/8a), we show how the route and dose alter the magnitude and quality of neoantigen-specific CD8+ T cells. Intravenous vaccination (SNP-IV) induced a higher proportion of TCF1+PD-1+CD8+ T cells as compared to subcutaneous immunization (SNP-SC). Single-cell RNA sequencing showed that SNP-IV induced stem-like genes (Tcf7, Slamf6, Xcl1) whereas SNP-SC enriched for effector genes (Gzmb, Klrg1, Cx3cr1). Stem-like cells generated by SNP-IV proliferated and differentiated into effector cells upon checkpoint blockade, leading to superior antitumor response as compared to SNP-SC in a therapeutic model. The duration of antigen presentation by dendritic cells controlled the magnitude and quality of CD8+ T cells. These data demonstrate how to optimize antitumor immunity by modulating vaccine parameters for specific generation of effector or stem-like CD8+ T cells.

immunology
Immune Activation Profiles Elicited by Distinct, Repeated TLR Agonist Infusions in Rhesus Macaques

Hannah A D King,Supriya Pokkali,Dohoon Kim,Daniel Brammer,Kaimei Song,Elizabeth McCarthy,Chelsea Lehman,John-Paul Todd,Kathryn E Foulds,Patricia A Darrah,Robert A Seder,Diane L Bolton,Mario Roederer

DOI: https://doi.org/10.4049/jimmunol.2300424

2023-12-01

Abstract:TLR agonists are a promising class of immune system stimulants investigated for immunomodulatory applications in cancer immunotherapy and viral diseases. In this study, we sought to characterize the safety and immune activation achieved by different TLR agonists in rhesus macaques (Macaca mulatta), a useful preclinical model of complex immune interactions. Macaques received one of three TLR agonists, followed by plasma cytokine, immune cell subset representation, and blood cell activation measurements. The TLR4 agonist LPS administered i.v. induced very transient immune activation, including TNF-α expression and monocyte activation. The TLR7/8 agonist 2BXy elicited more persistent cytokine expression, including type I IFN, IL-1RA, and the proinflammatory IL-6, along with T cell and monocyte activation. Delivery of 2BXy i.v. and i.m. achieved comparable immune activation, which increased with escalating dose. Finally, i.v. bacillus Calmette-Guérin (BCG) vaccination (which activates multiple TLRs, especially TLR2/4) elicited the most pronounced and persistent innate and adaptive immune response, including strong induction of IFN-γ, IL-6, and IL-1RA. Strikingly, monocyte, T cell, and NK cell expression of the proliferation marker Ki67 increased dramatically following BCG vaccination. This aligned with a large increase in total and BCG-specific cells measured in the lung. Principal component analysis of the combined cytokine expression and cellular activation responses separated animals by treatment group, indicating distinct immune activation profiles induced by each agent. In sum, we report safe, effective doses and routes of administration for three TLR agonists that exhibit discrete immunomodulatory properties in primates and may be leveraged in future immunotherapeutic strategies.

Effect of pregnancy on vasopressin-mediated responses in guinea-pig uterine arteries with intact and denuded endothelium.

Virulence‐Free Reconstituted Synthetic Nanopathogen Empowered by Timely‐Activating TLR Agonist Promotes Heterologous Cancer Immunotherapy with Depletion of Tumor‐Specific Treg Cells

Abstract 6743: Identifying new cellular adjuvants for cancer vaccines and immunotherapies

Enhanced Vaccine Immunogenicity Enabled by Targeted Cytosolic Delivery of Tumor Antigens into Dendritic Cells

Abstract 5747: A novel combination therapy of arenavirus vectors and PD1-IL2v strongly potentiates tumor specific T cell responses resulting in synergistic anti-tumor efficacy

Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity

Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy

Exploiting bacterial-origin immunostimulants for improved vaccination and immunotherapy: current insights and future directions

Abstract 481: Proteomimetic polymers limit tumor growth in multiple models via potent antigen-specific T cell activation

Pattern recognition receptors and their nano-adjuvants for cancer immunotherapy

Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

Which postsynaptic action of dopamine is mediated by cycle AMP?

Abstract A021: A cancer immunotherapy modality based on dendritic cell reprogramming in vivo

STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation

Outer Membrane Vesicle‐Based Nanohybrids Target Tumor‐Associated Macrophages to Enhance Trained Immunity‐Related Vaccine‐Generated Antitumor Activity

Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization

Vaccination against neoantigens induced in cross-priming cDC1 in vivo

Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity

Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity

Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells

Immune Activation Profiles Elicited by Distinct, Repeated TLR Agonist Infusions in Rhesus Macaques